Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are an important therapy for patients with type 2 diabetes (T2D) given their ability to improve glucose metabolism and their associated weight loss, low risk for hypoglycemia and positive effects on cardiovascular outcomes (1, 2). The gene discussed is GCG; the disease is type 2 diabetes mellitus.